Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years

  • Technology appraisal guidance
  • TA131
  • Published: 
Download guidance (PDF)

Appendix B. Sources of evidence considered by the Committee

A. The assessment report for this appraisal was prepared by Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School and Southampton Health Technology Assessments Centre (SHTAC), Wessex Institute for Health Research and Development (WIHRD), University of Southampton.

  • Main C, Shepherd J, Anderson R, et al, Inhaled corticosteroids and long-acting beta2-agonists for the treatment of chronic asthma in children under the age of 12 years: systematic review and economic analysis, December 2006

B. The following organisations accepted the invitation to participate in this appraisal. They were invited to comment on the draft scope, assessment report and the appraisal consultation document (ACD). Organisations listed in I and II were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination.

Manufacturers/sponsors:

  • AstraZeneca UK Ltd

  • GlaxoSmithKline UK Ltd

  • IVAX Pharmaceuticals UK Ltd

  • TEVA UK Ltd

  • Ranbaxy UK Limited

  • Trinity-Chiesi Pharmaceuticals Ltd (Trinity Pharmaceuticals Ltd)

  • Meda Pharmaceuticals Ltd

Professional/specialist and patient/carer groups:

  • Action Against Allergy (AAA)

  • Action for Sick Children

  • Allergy UK

  • Asthma UK

  • British Paediatric Respiratory Society

  • British Thoracic Society

  • Cochrane Airways Group

  • Department of Health

  • Education for Health

  • General Practice Airways Group (GPIAG)

  • Knowsley PCT

  • Royal College of General Practitioners

  • Royal College of Nursing

  • Royal College of Paediatrics and Child Health

  • Royal College of Physicians

  • Royal College of Physicians of Edinburgh

  • Welsh Assembly Government

Commentator organisations (without the right of appeal):

  • Asthma And Allergy Research Group, University of Dundee

  • AstraZeneca UK Ltd

  • British National Formulary

  • GlaxoSmithKline UK Ltd

  • IVAX Pharmaceuticals UK Ltd

  • Meda Pharmaceuticals Ltd

  • Medicines and Healthcare products Regulatory Agency (MHRA)

  • National Coordinating Centre for Health Technology Assessment

  • NHS Quality Improvement Scotland

  • Peninsula Technology Assessment Group (PenTAG)

  • Ranbaxy UK Limited

  • Respiratory Research Group, University of Glasgow

  • Southampton Health Technology Assessment Centre (SHTAC), University of Southampton

  • TEVA UK Ltd

  • Trinity – Chiesi Pharmaceuticals Ltd (Trinity Pharmaceuticals Ltd)

C. The following individuals were selected from clinical specialist and patient advocate nominations from the non-manufacturer/sponsor consultees and commentators. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on corticosteroids for the treatment of chronic asthma in children under 12 years by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Jonathan Grigg, Professor of Paediatric and Respiratory Medicine, nominated by Royal College of Paediatrics and Child Health – clinical specialist

  • Dr Mike Thomas, External Affairs Liaison nominated by General Practice Airways Group – clinical specialist

  • Ms Sally Rose, Asthma Nurse Specialist, nominated by Asthma UK – patient expert